EGFR and non-small cell lung carcinoma: When substratified by SYK-high status, all EGFR-mutant-positive NSCLC patients responded to EGFRis (ORR, 100%), and their response rate was much higher than the response rate of patients stratified by EGFR mutation alone (ORR, 74.2%).